Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-24-106072
Filing Date
2024-09-12
Accepted
2024-09-12 19:14:44
Documents
1
Period of Report
2024-09-12

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 10226
  Complete submission text file 0000950170-24-106072.txt   12974
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Reporting) CIK: 0001055951 (see all company filings)

State of Incorp.: DE
Type: 3 | Act: 34 | File No.: 001-42272 | Film No.: 241296069

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 212-739-6491
OrbiMed Capital GP VII LLC (Reporting) CIK: 0001760648 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-42272 | Film No.: 241296068

Mailing Address 12406 HORESHAM STREET CARMEL IN 46032
Business Address 12406 HORESHAM STREET CARMEL IN 46032 3179893100
MBX Biosciences, Inc. (Issuer) CIK: 0001776111 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
OrbiMed Genesis GP LLC (Reporting) CIK: 0001808744 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-42272 | Film No.: 241296067